<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 1 月 14 日至 2026 年 5 月 6 日（包括该日期）期间购买 Zoetis Inc.（纽约证券交易所代码：ZTS）证券的投资者，注意 2026 年 7 月 27 日的重要首席原告截止日期。</p>
<p>那么，接下来该怎么办：如果您在该期间购买了 Zoetis 证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Zoetis 集体诉讼，请访问 https://rosenlegal.com/cases/zoetis-inc/join 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 27 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有相应的经验、资源或任何有意义的同行认可。这些事务所中的许多实际上并不处理证券集体诉讼，而只是作为中介，转介客户或与实际诉讼案件的律师事务所合作。在选择律师时要明智。罗森律师事务所在全球范围内代表投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并夸大了市场份额、强劲的兽医采用率和 Zoetis 旗舰伴侣动物产品的销售增长，且未能披露：（1）兽医处方增长和 Zoetis 的 Librela（犬类疼痛治疗药物）的采用率因 FDA 关于犬类严重神经并发症的安全警告而急剧减弱；（2）Zoetis 的 Simparica Trio 在整体市场放缓的情况下，正失去大量市场份额给一种价格更低、适用范围更广的竞争犬类驱虫药；（3）Zoetis 的皮肤病产品 Apoquel 和 Cytopoint 正失去大量市场份额给一种新推出的竞争犬类治疗药物。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Zoetis 集体诉讼，请访问 https://rosenlegal.com/cases/zoetis-inc/join 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请在 LinkedIn 上关注我们以获取更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约，NY 10016</p>
<p>电话：（212）686-1060</p>
<p>免费电话：（866）767-3653</p>
<p>传真：（212）202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjEwJk5ld3NJdGVtSWQ9REM4MDk3NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTAxOTQ1UFJfTkVXU19VU1BSX19fX19EQzgwOTc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjEwJk5ld3NJdGVtSWQ9REM4MDk3NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTAxOTQ1UFJfTkVXU19VU1BSX19fX19EQzgwOTc3"/></p>

硕腾

<p>罗斯律师事务所提醒在 2025 年 1 月 14 日至 2026 年 5 月 6 日期间购买了 Zoetis Inc.（纽约证券交易所代码：ZTS）证券的投资者，申请作为证券欺诈集体诉讼的首席原告的截止日期为 2026 年 7 月 27 日。诉讼指控 Zoetis 在市场份额和销售增长方面做出了误导性陈述，同时未能披露由于 FDA 警告和竞争导致的 Librela 和 Simparica Trio 等产品的处方趋势减弱</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the &#34;Class Period&#34;), of the important July 27, 2026 lead plaintiff deadline.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 1 月 14 日至 2026 年 5 月 6 日（包括该日期）期间购买 Zoetis Inc.（纽约证券交易所代码：ZTS）证券的投资者，注意 2026 年 7 月 27 日的重要首席原告截止日期。</p>
</div><p>So What: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么，接下来该怎么办：如果您在该期间购买了 Zoetis 证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Zoetis 集体诉讼，请访问 https://rosenlegal.com/cases/zoetis-inc/join 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 27 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有相应的经验、资源或任何有意义的同行认可。这些事务所中的许多实际上并不处理证券集体诉讼，而只是作为中介，转介客户或与实际诉讼案件的律师事务所合作。在选择律师时要明智。罗森律师事务所在全球范围内代表投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并夸大了市场份额、强劲的兽医采用率和 Zoetis 旗舰伴侣动物产品的销售增长，且未能披露：（1）兽医处方增长和 Zoetis 的 Librela（犬类疼痛治疗药物）的采用率因 FDA 关于犬类严重神经并发症的安全警告而急剧减弱；（2）Zoetis 的 Simparica Trio 在整体市场放缓的情况下，正失去大量市场份额给一种价格更低、适用范围更广的竞争犬类驱虫药；（3）Zoetis 的皮肤病产品 Apoquel 和 Cytopoint 正失去大量市场份额给一种新推出的竞争犬类治疗药物。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Zoetis 集体诉讼，请访问 https://rosenlegal.com/cases/zoetis-inc/join 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以选择保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请在 LinkedIn 上关注我们以获取更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约，NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：（212）686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：（866）767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：（212）202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjEwJk5ld3NJdGVtSWQ9REM4MDk3NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTAxOTQ1UFJfTkVXU19VU1BSX19fX19EQzgwOTc3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC80977&amp;Transmission_Id=202606101945PR_NEWS_USPR_____DC80977&amp;DateId=20260610"/></p>

19:45 ETZTS 投资者有机会主导对硕腾公司的证券欺诈诉讼